Drug intelligence / Profile preview

divarasib + migoprotafib

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **divarasib**, a next-generation covalent KRAS G12C inhibitor, and **migoprotafib**, an SHP2 inhibitor. The combination is being studied for its potential in treating KRAS G12C-positive non-small cell lung cancer (NSCLC). The rationale behind combining these drugs is to enhance the efficacy of KRAS G12C inhibition by targeting SHP2, which mediates RAS signaling pathways.

Other names: divarasib + GDC-1971

Targets

PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on divarasib + migoprotafib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on divarasib + migoprotafib.

Explore the full profile